FDA knocks Stryker's Wingspan stent

Stryker ($SYK) is facing a sobering FDA report that points to the company's Wingspan stent as being more damaging than helpful in some cases and of neutral benefit in others, according to a Bloomberg story. Regulators said that blood thinners and other standard therapies for stroke prevention could be better alternatives in certain situations than the stent itself, which gained approval in 2005 under a humanitarian device exemption. Their assessment follows an NIH study, published in September, concluding the Wingspan stent was more likely to cause strokes in patients than drug treatments, the story notes. An FDA panel of experts will meet March 23 to review Wingspan's safety and effectiveness. Story

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.